Journal Information
Vol. 99. Issue 4.
Pages 291-296 (May 2008)
Share
Share
Download PDF
More article options
Vol. 99. Issue 4.
Pages 291-296 (May 2008)
Case reports
Full text access
Cutaneous Follicular Center B-Cell Lymphoma Treated With Intralesional Rituximab
Linfoma Cutáneo de Células B del Centro Folicular Tratado Con Rituximab Intralesional
Visits
6094
R. Gamoa,
Corresponding author
reyesgamo@vodafone.es
rgamo@fhalcorcon.es

Correspondence: Departamento de Dermatología, Hospital Fundación Alcorcón, Avda Budapest, 1, 28922 Alcorcón, Madrid, Spain.
, L. Calzadoa, F. Pinedob, J.L. López-Estebaranza
a Servicio de Dermatología, Hospital Fundación Alcorcón, Alcorcón, Madrid, Spain
b Servicio de Anatomía Patológica, Hospital Fundación Alcorcón, Alcorcón, Madrid, Spain
This item has received
Article information
Abstract
Bibliography
Download PDF
Statistics
Abstract

Cutaneous follicular center B-cell lymphomas are indolent tumors characterized by the presence of neoplastic follicular center cells. They contain a mixture of centrocytes with a variable number of centroblasts. The tumor is usually treated by surgery or radiotherapy, although other treatments may be used such as interferon-α, chemotherapy, and biological agents (rituximab). Rituximab is a chimeric monoclonal anti-CD20 antibody that can be administered intravenously or intralesionally. We report the case of a 41-year-old man who consulted for violaceous nodular lesions in the left scapular region and who was diagnosed with cutaneous follicular center B-cell lymphoma after biopsy, laboratory tests, thoracic-abdominal-pelvic computed tomography, abdominal ultrasound, and bone marrow biopsy. It was decided to treat him with 30mg of intralesional rituximab administered for 1 week (3 times) every month for 4 months. Complete response was obtained. We also review the published cases of cutaneous B-cell lymphoma treated with intralesional rituximab.

Key words:
B-cell lymphoma
follicular center B-cell lymphoma
rituximab
intralesional
Resumen

Los linfomas cutáneos de células B del centro folicular son tumores indolentes compuestos por células neoplásicas del centro folicular. Están constituidos por una mezcla de centrocitos con un número variable de centroblastos. Los tratamientos habitualmente utilizados son la cirugía y la radioterapia, aunque se utilizan otros como el interferón-α (IFN-α), la quimioterapia y tratamientos biológicos (rituximab). El rituximab es un anticuerpo monoclonal quimérico anti-CD20. Puede utilizarse por vía intravenosa o intralesional. Presentamos el caso de un paciente varón de 41 años que consultó por lesiones nodulares violáceas en el área escapular izquierda y que, tras la realización de una biopsia, analítica, tomografía axial computarizada (TAC) toracoabdominopélvica, ecografía abdominal y biopsia de médula ósea fue diagnosticado de linfoma cutáneo de células B del centro folicular. Se decidió tratamiento con 30mg de rituximab intralesional, tres veces a la semana, una vez al mes, durante 4 meses, con respuesta completa. Realizamos una revisión de los casos de linfoma cutáneo de células B tratados con rituximab intralesional.

Palabras clave:
linfoma cutáneo de células B
linfoma B del centro folicular
rituximab
intralesional
Full text is only aviable in PDF
References
[1.]
P.L. Ortiz-Romero, C. Zarco, D. De Argila.
Linfomas y pseudolinfomas cutáneos. Tratado de Dermatología.
2a ed., Mac Graw Hill, S.A., (2004),
[2.]
B. Dreno.
Standard and new treatments in cutaneous B-cell lymphomas.
J Cutan Pathol, 33 (2006), pp. 47-51
[3.]
J. Pedraz, Y. Delgado, M. Aragues, J. Fraga, A. García-Díez, J. Fernández-Herrera.
Cutaneous marginal zone B-cell lymphoma treated with rituximab.
Actas Dermosifiliogr, 96 (2005), pp. 593-597
[4.]
L. Heinzerling, R. Dummer, W. Kempf, M.H. Schmid, G. Burg.
Intralesional therapy with anti-CD20 monoclonal antibody rituximab in primary cutaneous B-cell lymphoma.
Arch Dermatol, 136 (2000), pp. 374-378
[5.]
T. Paul, P. Radny, S.M. Krober, A. Paul, H.J. Blaheta, C. Garbe.
Intralesional rituximab for cutaneous B-cell lymphoma.
Br J Dermatol, 144 (2001), pp. 1239-1243
[6.]
A.M. Roguedas, H. Watier, G. Paintaud, A. de Muret, L. Vaillant, L. Machet.
Intralesional therapy with anti-CD20 monoclonal antibody rituximab: local and systemic efficacy in primary cutaneous B-cell lymphoma.
Br J Dermatol, 152 (2005), pp. 541-544
[7.]
R. Fink-Puches, I.H. Wolf, I. Zalaudek, H. Kerl, L. Cerroni.
Treatment of primary cutaneous B-cell lymphoma with rituximab.
J Am Acad Dermatol, 52 (2005), pp. 847-853
[8.]
M.C. Kyrtsonis, M.P. Siakantaris, C. Kalpadakis, M.N. Dimopoulou, T.P. Vassilakopoulos, F.N. Kontopidou, et al.
Favourable outcome of primary cutaneous marginal zone lymphoma treated with intralesional rituximab.
Eur J Haematol, 77 (2006), pp. 300-303
[9.]
K. Kerl, C. Prins, J.H. Saurat, L.E. French.
Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases.
Br J Dermatol, 155 (2006), pp. 1197-2000
Copyright © 2008. Academia Española de Dermatología y Venereología and Elsevier España, S.L.
Download PDF
Idiomas
Actas Dermo-Sifiliográficas
Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?